Published 1 year ago • loading... • Updated 1 year ago

Once-Yearly Lenacapavir PrEP a Safe, Promising Alternative to Twice-Yearly Dosing

(MedPage Today) -- SAN FRANCISCO -- A once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of plasma concentrations compared with twice-yearly subcutaneous lenacapavir for HIV pre...

19 Articles

Kurier

Lean Right

HIV: "If many are afraid of something, a stigma will emerge"

For more than 40 years, research into the HIV virus has been carried out worldwide. Successful in many ways. Fighting against certain pitfalls of the pathogen and prejudices are still taking place today.

1 year ago·Vienna, Austria

Read Full Article

MedPage Today

Reposted by

Anti-Aging, Acupuncture and Health News

Center

Once-Yearly Lenacapavir PrEP a Safe, Promising Alternative to Twice-Yearly Dosing

1 year ago·New York, United States

Read Full Article

MIT Technology Review

Center

This annual shot might protect against HIV infections

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

1 year ago·Cambridge, United States

Read Full Article

ajmc.com

Center

Priorities for Optimizing HIV Care in Children and Adolescents

Priscilla Tsondai, MD, MPH, breaks down top care gaps as opportunities for care improvement.

1 year ago

Read Full Article

IOL

Center

Hope for HIV prevention: Annual injection completes important safety trial

1 year ago·Cape Town, South Africa

Read Full Article

Contagion Live

Center

HIV Prevention: Discussing PrEP, PEP, and Vaccine Development

Colleen Kelley, MD, MPH, offers some insights on where we are today with the state of HIV prevention including the expanding PrEP options, why PEP is underutilized, and the challenges behind HIV vaccine development.

1 year ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year